A new CAR-T therapy shows efficacy in preclinical models of hard-to-treat leukemias
Researchers from Clínic-IDIBAPS, within the Clínic Barcelona Comprehensive Cancer Center, and the spin-off Gyala Therapeutics have coordinated a stud1
Researchers from Clínic-IDIBAPS, within the Clínic Barcelona Comprehensive Cancer Center, and the spin-off Gyala Therapeutics have coordinated a stud1
An international team led by the Clínic-IDIBAPS and the Institute of Cancer Research in London has developed an innovative new method based on DNA me1
September 1st is World Chronic Lymphocytic Leukaemia (CLL) Day, the most common leukaemia in adults. Most patients with CLL respond well to treatment1
This discovery changes the view of the progression of leukaemia, opens the door to early diagnosis, and offers new treatment strategies.
The call for the presentation of applications for the I Estella Matutes Extraordinary Scholarship is open from September 19th to November 30th.
The grants from the European Haematology Association (EHA) are aimed at promoting the early careers of researchers and encouraging their involvement1
Researchers from IDIBAPS-Hospital Clínic and CNAG-CRG in Barcelona have led a study to draw the first 3D maps of the genome of healthy and cancerous1
The Spanish Agency of Medicines and Medical Devices (AEMPS) has approved CAR-T ARI-0001, developed by Hospital Clínic, as and advanced therapy drug o1
Immuneel Therapeutics Private Limited (Immuneel) today announced that it has entered into a multi-asset collaboration and licensing agreement with Ho1
A consortium of researchers from the Cancer Research Center of Ontario and the Hospital for Sick Children of Toronto, the Hospital Clínic-IDIBAPS of1